Skip to main content

Articles

Page 6 of 6

  1. Typically, metal-based radiopharmaceuticals are synthesized in aqueous solutions with no or low ethanol content. Labeling yields are defined by temperature, period of labeling, amount of precursor, pH etc. As ...

    Authors: Elisabeth Eppard, Marylaine Pèrez-Malo and Frank Rösch
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:6

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  2. 149Tb represents a powerful alternative to currently used α-emitters: the relatively short half-life (T1/2 = 4.1 h), low α-energy (3.97 MeV, Iα = 16.7 %), absence of α-emitting daughters and stab...

    Authors: Cristina Müller, Christiaan Vermeulen, Ulli Köster, Karl Johnston, Andreas Türler, Roger Schibli and Nicholas P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:5

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  3. The widespread acceptance and application of 68Ga-PET depends on our ability to develop radiopharmaceuticals that can be prepared in a convenient and suitable manner. A kit-type labelling protocol provides such c...

    Authors: Johanna Seemann, Bradley Waldron, David Parker and Frank Roesch
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:4

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  4. Phosphodiesterase 10A (PDE10A) is an important regulator of nigrostriatal dopamine (DA) neurotransmission. However, little is known on the effect of alterations in DA neurotransmission on PDE10A availability. ...

    Authors: Maarten Ooms, Sofie Celen, Ronald De Hoogt, Ilse Lenaerts, Johnny Liebregts, Greet Vanhoof, Xavier Langlois, Andrey Postnov, Michel Koole, Alfons Verbruggen, Koen Van Laere and Guy Bormans
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:3

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  5. This is a position paper of the Radiopharmacy Committee of the EANM (European Association of Nuclear Medicine) addressing toxicology studies for application of new diagnostic and therapeutic radiopharmaceutica...

    Authors: J. Koziorowski, M. Behe, C. Decristoforo, J. Ballinger, P. Elsinga, V. Ferrari, P. Kolenc Peitl, S. Todde and T. L. Mindt
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:1

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

EJNMMI Reports - Kindly explore our collections here

Topical Collections about latest and interesting topics in EJNMMI Radiopharmacy and Chemistry are available at: https://link.springer.com/journal/41824/collections

EANM'24 - Future Congress!

EANM'24 banner horizontal

Future Congress

37th Annual Congress of the European Association of Nuclear Medicine

October 19 – 23, 2024
Hamburg, Germany


CCH – Congress Center Hamburg
Congressplatz 1
20355 Hamburg, Germany
URL: https://www.cch.de/en/

EJNMMI Journal Family and EANM Springer Award

New Content Item

EJNMMI is part of the EJNMMI Journal Family. Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There details about the annual EANM Springer Award are available as well.


Do you want to publish your paper open access?

Details of the OpenChoice option in EJNMMI are available in the submission guidelines.

If your institution has a Read and Publish (Springer Compact) agreement, you may publish your article open access at no cost to you. In addition, you can enjoy full access to all Springer subscription journal content.

Please check the agreement details by participating country here.